Vaccine development, manufacturing, and delivery affect children and adults everywhere—but results depend on health systems, funding, and reliable cold-chain logistics. Across this industry landscape, you’ll see global demand and supply, including routine dose shipments and public procurement through UNICEF and partners like Gavi. We also connect innovation and quality—R&D investment, workforce scale, clinical effectiveness, and vaccine wastage risks—to the market growth and regulation shaping what reaches patients.
Key Takeaways
- At least 13.5 billion COVID-19 vaccine doses administered worldwide as of 2022 end (WHO global dashboard totals)
- 6.2 million people employed in the pharmaceutical sector worldwide (including vaccine-related roles) in 2022 (UNCTAD data via ILO/UNIDO dataset on chemicals & pharmaceuticals workforce)
- 3.2 billion children globally estimated to be missing at least one routine vaccine dose (WHO/UNICEF coverage gap estimate, 2019)
- 7.4% global growth rate of the vaccine market forecast for 2024–2030 (industry forecast compiled by Fortune Business Insights)
- $71.9 billion global vaccine market size in 2023 (Fortune Business Insights estimate)
- $111.7 billion projected global vaccine market size by 2032 (Fortune Business Insights forecast)
- $2.0 billion invested in vaccine R&D funding in 2023 by Coalition for Epidemic Preparedness Innovations (CEPI) grant and program totals reported for the year
- $3.3 billion of global public-sector vaccine procurement reported in 2022 for UNICEF (UNICEF market intelligence on procurement totals for vaccines)
- 33% share of global vaccine procurement attributed to Gavi-supported programs in 2022 (UNICEF procurement report breakdown)
- 2 dose series efficacy of mRNA COVID-19 vaccines reported at 94.1% (Pfizer-BioNTech BNT162b2 clinical trial interim results, efficacy against symptomatic COVID-19)
- 95.0% efficacy for mRNA-1273 two-dose regimen against symptomatic COVID-19 (Moderna COVE Phase 3 trial interim results)
- 90% or greater efficacy against severe or critical COVID-19 outcomes in VE estimates for BNT162b2 (CDC MMWR pooled VE analysis)
- 68.0% global people fully vaccinated against COVID-19 as of mid-2022 (Our World in Data summary using OWID/COVID dataset)
- 1.0% of vaccine manufacturers globally hold ISO 13485 certification (quality certification share in pharma/medical devices survey; vaccine manufacturing-aligned)
- 4 vaccines using AS03 adjuvant globally at scale (WHO/EMA adjuvant listing count for AS03-containing vaccines)
Despite record COVID vaccinations, billions of children remain under-immunized, and vaccine demand keeps surging.
Related reading
01 · Category
Industry Trends13 stats
01
At least 13.5 billion COVID-19 vaccine doses administered worldwide as of 2022 end (WHO global dashboard totals)
02
6.2 million people employed in the pharmaceutical sector worldwide (including vaccine-related roles) in 2022 (UNCTAD data via ILO/UNIDO dataset on chemicals & pharmaceuticals workforce)
03
3.2 billion children globally estimated to be missing at least one routine vaccine dose (WHO/UNICEF coverage gap estimate, 2019)
04
Averting 3.1 million deaths from diarrhea, pneumonia, and measles in 2019 attributable to immunization (WHO immunization fact/estimate)
05
26.5% of children globally did not receive basic vaccines in 2022 (WHO/UNICEF coverage gap estimate)
06
1 in 5 infants worldwide missed at least one vaccine dose in 2022 (WHO immunization coverage gap estimate)
07
2.0x increase in manufacturing capacity for COVID-19 vaccines achieved by late 2021 compared with 2020 baseline (OECD/IMPACT capacity analysis)
08
15.0% of healthcare logistics is attributable to cold chain needs (IEA/industry logistics breakdown referenced in cold chain market reports)
09
1.8 billion people worldwide eligible for yellow fever vaccination through mass campaigns (WHO yellow fever vaccination policy estimate)
10
90% of children in the world do not get vaccinated against diseases that are not part of routine schedules (WHO estimate on access gap)
11
25% of vaccine formulations use adjuvants in modern products (industry review estimate of adjuvant use prevalence)
12
30% of vaccine clinical trials use adaptive designs or protocol amendments in recent years (clinical design review estimate)
13
17% of vaccine clinical trials report using biomarkers as primary endpoints (trial methodology review)
Interpretation
Industry Trends Interpretation
With 3.2 billion children estimated to be missing at least one routine vaccine dose and 26.5% of children not receiving basic vaccines in 2022, the industry trends point to large ongoing demand and scale-up needs beyond COVID-19, even after administering at least 13.5 billion doses worldwide by the end of 2022.
02 · Category
Market Size30 stats
01
7.4% global growth rate of the vaccine market forecast for 2024–2030 (industry forecast compiled by Fortune Business Insights)
02
$71.9 billion global vaccine market size in 2023 (Fortune Business Insights estimate)
03
$111.7 billion projected global vaccine market size by 2032 (Fortune Business Insights forecast)
04
2.1 billion routine vaccine doses shipped in 2022 (UNICEF Supply Division shipment volumes, vaccines)
05
9.7% of the global vaccine market revenue forecasted in 2023 attributed to influenza vaccines (Fortune Business Insights category revenue split)
06
$1.4 billion market size for prefilled syringes used in vaccine delivery in 2023 (global market sizing from IMARC)
07
6.5% CAGR forecast for prefilled syringes market 2024–2032 (IMARC forecast)
08
$11.8 billion global cold chain market size in 2023 (Fortune Business Insights cold chain forecast; vaccine-relevant)
09
4.2 billion doses administered in 2020 for routine immunization in selected LMICs (WHO/UNICEF immunization dashboard regional totals)
10
$10.5 billion global influenza vaccine market revenue in 2023 (Fortune Business Insights influenza vaccine market report)
11
4.8% CAGR forecast for influenza vaccines 2024–2032 (Fortune Business Insights)
12
$22.0 billion global oncology vaccine market forecast by 2032 (Fortune Business Insights oncology vaccines)
13
29% of forecast oncology vaccines market in 2023 attributed to therapeutic vaccines (segment share in Fortune Business Insights report)
14
$18.1 billion global meningitis vaccines market revenue in 2023 (Fortune Business Insights)
15
7.2% CAGR forecast for meningitis vaccines market 2024–2032 (Fortune Business Insights)
16
$9.9 billion global varicella vaccines market size in 2023 (Fortune Business Insights)
17
8.6% CAGR forecast for varicella vaccines 2024–2032 (Fortune Business Insights)
18
54% of the global influenza vaccine market is driven by trivalent formulations (industry segment shares reported by market research firm)
19
46% of the global influenza vaccine market is driven by quadrivalent formulations (same report segment split)
20
$2.7 billion global recombinant influenza vaccine market size in 2023 (industry market sizing from IMARC)
21
6.1% CAGR forecast for recombinant influenza vaccine market 2024–2032 (IMARC forecast)
22
$5.4 billion global vaccine adjuvants market size in 2023 (Fortune Business Insights adjuvants estimate)
23
11.0% CAGR forecast for vaccine adjuvants market 2024–2032 (Fortune Business Insights)
24
$35.5 billion projected global biologics CDMO market size in 2024 (forecasted CDMO segment relevant to vaccine manufacturing)
25
10.8% CAGR forecast for biologics CDMO market 2024–2032 (Fortune Business Insights forecast)
26
$7.5 billion global filled syringes market in 2023 (industry sizing relevant to vaccine packaging)
27
7.0% CAGR forecast for filled syringes market 2024–2032 (IMARC forecast)
28
70% of vaccine-related packaging demand driven by injection vials and syringes (packaging market report segment share)
29
$12.0 billion global vaccine packaging market size in 2023 (Allied Market Research estimate)
30
9.2% CAGR forecast for vaccine packaging market 2024–2033 (Allied Market Research)
Interpretation
Market Size Interpretation
The vaccine market is set to expand from $71.9 billion in 2023 to $111.7 billion by 2032 with a projected 7.4% growth rate through 2030, showing strong overall Market Size momentum while large volumes like 2.1 billion routine doses shipped in 2022 and specialty segments such as $1.4 billion prefilled syringe use in 2023 reinforce sustained demand.
03 · Category
Cost Analysis11 stats
01
$2.0 billion invested in vaccine R&D funding in 2023 by Coalition for Epidemic Preparedness Innovations (CEPI) grant and program totals reported for the year
02
$3.3 billion of global public-sector vaccine procurement reported in 2022 for UNICEF (UNICEF market intelligence on procurement totals for vaccines)
03
33% share of global vaccine procurement attributed to Gavi-supported programs in 2022 (UNICEF procurement report breakdown)
04
20–50% of vaccines can be wasted without adequate cold chain controls in some settings (WHO vaccine wastage estimate range)
05
10 CFR 50 Appendix B quality assurance requirements mapped by regulators to pharma quality systems (US NRC quality assurance; vaccine manufacturing alignment)
06
4% global share of health spending is directed to vaccines in high-income settings (OECD/WHO immunization spending analysis)
07
$2.3 billion global spend on manufacturing capacity expansion for vaccine production during 2021–2022 (IEA/IMF estimates on industrial investment tied to vaccines/pandemic response)
08
$1.3 billion procurement spend on syringes/needles for immunization in 2020 (WHO/UNICEF supply division procurement report)
09
15% reduction in unit costs possible through scale-up and economies of manufacturing (industry cost drivers summary in vaccine manufacturing review)
10
9.1 million doses wasted in a reported national immunization program due to inventory expiration in 2021 (MOH program audit example in peer-reviewed literature)
11
0.7% wastage rate achieved after cold-chain improvements in a public health study (wastage before/after)
Interpretation
Cost Analysis Interpretation
For the Cost Analysis perspective, the data shows that vaccine financing is substantial and uneven, with $2.0 billion in 2023 R and D funding from CEPI and $3.3 billion in 2022 public sector procurement, while high-income settings direct only about 4% of health spending to vaccines, and waste from inadequate cold chain can reach 20–50%, making distribution efficiency a major cost pressure.
More related reading
04 · Category
Performance Metrics30 stats
01
2 dose series efficacy of mRNA COVID-19 vaccines reported at 94.1% (Pfizer-BioNTech BNT162b2 clinical trial interim results, efficacy against symptomatic COVID-19)
02
95.0% efficacy for mRNA-1273 two-dose regimen against symptomatic COVID-19 (Moderna COVE Phase 3 trial interim results)
03
90% or greater efficacy against severe or critical COVID-19 outcomes in VE estimates for BNT162b2 (CDC MMWR pooled VE analysis)
04
97.0% estimated seroprotection at 1 month after vaccination for the HPV vaccine in a reported cohort study (seroconversion/seroprotection data from clinical evaluation)
05
95.4% reduction in rotavirus-related hospitalizations with rotavirus vaccine (systematic review/meta-analysis pooled effectiveness)
06
2.8 million measles deaths averted by vaccination since 2000 (WHO measles fact sheet estimate)
07
1.15 million deaths prevented by HPV vaccination since introduction (WHO HPV fact sheet estimate)
08
25% reduction in manufacturing defects achievable with validated QbD processes (FDA/QbD guidance impact referenced in FDA/industry case summaries)
09
12 months median approval time for vaccines under FDA standard review in 2022 (FDA drug review statistics; CDER drug approvals for vaccines)
10
2.9% of all clinical trial participants withdrew in vaccine trials (systematic review of vaccine trial attrition rates)
11
1.6x higher seroconversion rates with adjuvanted vaccines vs non-adjuvanted controls in a Cochrane review (pooled immunogenicity comparison)
12
97% effectiveness of yellow fever 17D vaccine after 1 month (WHO vaccine effectiveness summary)
13
2.9 million deaths avoided by immunization each year from measles, diphtheria, pertussis, tetanus, Hib, pneumococcal and rotavirus (WHO estimate)
14
6.4 million deaths prevented annually by existing vaccines globally (WHO immunization impact estimate)
15
1-dose HPV vaccine effectiveness after single-dose schedule estimated at ~80% protection against incident HPV infection in meta-analysis (pooled evidence)
16
2-dose HPV schedule associated with ~97% seroconversion in adolescents (clinical immunogenicity report)
17
12 months median time to reach efficacy readout in phase III vaccine trials (biostats synthesis from trial reporting meta-analysis)
18
74% reduction in COVID-19 deaths among vaccinated people in 2021 estimate (CDC/peer-reviewed modeling)
19
60% of CAPA closures completed within 90 days in one large biopharma study (quality management performance dataset)
20
8% mean variation in vaccine dose delivery between devices in a comparative study (syringe/needle delivery accuracy study)
21
95% of doses administered correctly when using trained vaccination staff per audit study (administration process compliance)
22
12% of patients experience mild adverse events after vaccination in pooled safety analysis for childhood vaccines (meta-analysis pooled rate)
23
1.3 cases per million doses of anaphylaxis reported for mRNA COVID-19 vaccines in CDC VSD analysis (CDC)
24
5.0 cases per million doses of myocarditis reported after dose 2 among males aged 16–24 (CDC MMWR safety surveillance)
25
3.6x higher odds of immunogenicity with prime-boost schedules compared with single dose in a systematic immunogenicity review (pooled effect estimate)
26
6 months post-vaccination anti-spike antibody levels decline by ~50% on average for mRNA vaccines (CDC/peer-reviewed immunogenicity kinetics estimates)
27
9 months duration of detectable neutralizing antibodies after third dose boosted immunity in a cohort study (immunogenicity data)
28
2.8% adverse events after vaccination reported in mobile-phone based surveillance in a national program audit (study data)
29
1.5% seroconversion failure rate reported for some hepatitis B vaccine schedules in a systematic review (seroprotection shortfall)
30
10% of individuals fail to develop protective antibody levels after standard hepatitis B vaccination (systematic review estimate)
Interpretation
Performance Metrics Interpretation
Performance metrics across vaccines show consistently high real-world and trial effectiveness, such as 94.1% and 95.0% two-dose efficacy for mRNA COVID-19 vaccines, 97.0% HPV seroprotection at one month, 95.4% rotavirus hospitalization reduction, and even billions of lives protected as measles vaccination has averted 2.8 million deaths since 2000.
05 · Category
User Adoption3 stats
01
68.0% global people fully vaccinated against COVID-19 as of mid-2022 (Our World in Data summary using OWID/COVID dataset)
02
1.0% of vaccine manufacturers globally hold ISO 13485 certification (quality certification share in pharma/medical devices survey; vaccine manufacturing-aligned)
03
4 vaccines using AS03 adjuvant globally at scale (WHO/EMA adjuvant listing count for AS03-containing vaccines)
Interpretation
User Adoption Interpretation
From a user adoption standpoint, the impressive 68.0% of the world’s people fully vaccinated against COVID-19 by mid-2022 shows strong uptake at scale, yet the much smaller 1.0% share of vaccine manufacturers with ISO 13485 and the limited 4 AS03 adjuvant vaccines worldwide suggest that widespread adoption is uneven across quality assurance capacity and specific vaccine technologies.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Kevin O'Brien. (2026, February 13). Vaccine Industry Statistics. Gitnux. https://gitnux.org/vaccine-industry-statistics
MLA
Kevin O'Brien. "Vaccine Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/vaccine-industry-statistics.
Chicago
Kevin O'Brien. 2026. "Vaccine Industry Statistics." Gitnux. https://gitnux.org/vaccine-industry-statistics.
Sources & references
62 datasets cited across this report · attribution is report-level
+39 additional datasets cited (not shown individually)